A Phase 2 interventional study of Tislelizumab and Nab-paclitaxel in Head and Neck Squamous Cell Carcinomas and Resectable Head and Neck Squamous-cell Carcinoma, sponsored by Xiang Lu. Recruiting at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-02-01.
Sponsored by Xiang Lu · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 16 studies testing tislelizumab in Squamous Cell Carcinoma of Head and Neck — 8 open to participants now, 13 under way, none of them phase 3. tislelizumab · Squamous Cell Carcinoma of Head and Neck.
Among the 16 studies testing tislelizumab in Squamous Cell Carcinoma of Head and Neck, this one is the 10th largest by planned enrollment, is one of 5 that started in 2023, is one of 12 in phase 2, reaches primary completion later than 2 of the 12 other live ones, and was the 10th registered.
2,023 studies on the registry are indexed under Squamous Cell Carcinoma of Head and Neck; 573 are open to participants now.
Browse Squamous Cell Carcinoma of Head and Neck studies →8 of the 16 studies testing tislelizumab in Squamous Cell Carcinoma of Head and Neck are open now, in 2 countries. Recruiting first, the newest first:
Daping Hospital and the Research Institute of Surgery of the Third Military Medical University · Sites in China
Ages 18+
Beijing Tongren Hospital · Sites in China
Ages 18+
Weijia Fang, MD · Sites in China
Ages 18–75
University of Chicago · Sites in United States
Ages 18+
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University · Sites in China
Ages 18–65
By country, each count listing its studies:
tislelizumab: first FDA approval 2024 (TEVIMBRA), first EMA approval 2023. What it is approved for, and how studies give it, is on its page →
Of the 434 Squamous Cell Carcinoma of Head and Neck studies recruiting now, 310 (71%) set no upper age limit and 87 (20%) stop at 75 or younger; 5 take children under 18; 13 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
16 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 4 · Phase 2 15
First in 2018; this study’s year is marked. 5 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 30 is below the median of 48 across 1,657 interventional studies indexed under Squamous Cell Carcinoma of Head and Neck.
Median enrollment 41 across the 16 interventional studies. Of the 2 that completed or were terminated, 1 (50%) have results posted.
This tab as a report to print or save as PDF → With an account.
2 of 16 have an industry lead sponsor. The 10 most frequent:
This is the only study on the registry with Xiang Lu as lead sponsor.
Xiang Lu has 1 study filed under Squamous Cell Carcinoma of Head and Neck — fewer than ten, so there is no comparison to draw.
3 of the studies testing tislelizumab in Squamous Cell Carcinoma of Head and Neck that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06725498Beijing Tongren HospitalIntra-arterial Chemotherapy Combined with Radiotherapy and Immunotherapy for HNSCC | 2026-11-30 |
| NCT06978829Daping Hospital and the Research Institute of Surgery of the Third Military Medical UniversityCetuximab + Tislelizumab + Chemotherapy in the Treatment of Unresectable LA HNSCC | 2027-03-31 |
| NCT07010120West China HospitalA Clinical Trial of Neoadjuvant Targeted Therapy, Immunotherapy, and Lysogenic HSV-Based Virotherapy in Resectable Head and Neck Squamous Cell Carcinoma | 2027-05-31 |
Add all 3 to your calendar (.ics) → With an account.
Among the 16 studies testing tislelizumab in Squamous Cell Carcinoma of Head and Neck, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
For resectable squamous cell carcinoma of the head and neck , novel therapeutic approaches are still needed to improve outcomes. Neoadjuvant immunochemotherapy is considered as a potentially effective strategy. The purpose of this study is to evaluate the safety and efficacy of neoadjuvant of tislelizumab combined with platinum doublet for resectable locally-advanced head and neck squamous-cell carcinoma .
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Neoadjuvant Tislelizumab plus double platinum based chemotherapy for 2 cycles
Drug: Tislelizumab · Drug: Nab-paclitaxel · Drug: Carboplatin
Tislelizumab: 200mg,administered via Intravenous (IV) injection, day 1 of each 21-day cycle, neoadjuvant therapy : 2 cycles
Also known as: BGB-A317
260mg/m\^2, IV, day 1 of each 21-day cycle, neoadjuvant therapy : 2 cycles
AUC 5 mg/mL/min by IV infusion once every 3 weeks,day 1 of each 21-day cycle,neoadjuvant therapy : 2 cycles
Pathological Complete Response (PCR)
Time frame: From neoadjuvant therapy to surgical resection, up to 6 weeks
Major Pathological Response (MPR)
In the pathological examination of resected specimens, the proportion of residual tumor cells was less than 10%.
Time frame: From neoadjuvant therapy to surgical resection, up to 6 weeks
3-year Disease-free survival (DFS) rate
Time from randomization to disease recurrence or death of any cause
Time frame: 3-years after surgery
3-year overall survival(OS)rate
The proportion of all study cases in which no death from any cause occurred within 3 years after surgery
Time frame: 3-years after surgery
Plan to share: No
No publications or documents are linked to this record.
Started Jan 2023 (actual). Primary completion is estimated for Jan 2025, 24 months after the start.
Of 299 non-industry phase 2 interventional studies under Squamous Cell Carcinoma of Head and Neck, half reached primary completion within 56 months of starting (the median), counting those still running; a quarter within 37 and three quarters within 85. This study's planned 24 months is below that.
Counting every sponsor, half of 366 studies reached it within 53 months; a quarter within 35 and three quarters within 82.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Tislelizumab
Squamous Cell Carcinoma of Head and Neck →